Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

Peter Grell(Masaryk Memorial Cancer Institute), Marek Svoboda(Masaryk Memorial Cancer Institute)

International Journal of Oncology

July 27, 2012

10.3892/ijo.2012.1576

Cited by 22

Related Papers

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

|JAMA Oncology|2023|73

Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.

|Journal of Clinical Oncology|2024|9